

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert M. Carlson et al.

Title: ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL

Docket No.: 1339.016US1

Serial No.: 10/816,804

Filed: April 2, 2004

Due Date: N/A

Examiner: Unknown

Group Art Unit: 1617

MS Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

X A return postcard.

X An Information Disclosure Statement (2 pgs.), Form 1449 (10 pgs.), and copies of 84 cited documents, including the International Search Report for corresponding PCT Application No. PCT/US2004/010351 (7 pgs.)

If not provided for in a separate paper filed herewith, Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

By: 

Atty: Gary J. Speier

Reg. No. 45,458

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 11th day of August, 2005.


JAMES KANYUSIK
Name


Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

S/N 10/816,804



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Robert M. Carlson et al.	Examiner:	Unknown
Serial No.:	10/816,804	Group Art Unit:	1617
Filed:	April 02, 2004	Docket:	1339.016US1
Title:	ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL		

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Several of the documents, listed on the attached 1449, were discovered as a result of a Search Report in Applicant's corresponding foreign patent application. Enclosed for the Examiner's information is a copy of the Search Report and copies of the following documents cited therein:

Ali-Shtayeh, et al, "Antifungal Activity of Plant Extracts Against Dermatophytes";

EP 0093563A2

EP 0824913A2

EP 1031348A2

GB 14768

GB 2051575

JP 01-290619

JP 11-012122

WO 02/26761A1

WO 03/092712A1

The concise explanation and relevance of the non-English language documents is believed to be provided by the category listing, e.g. "A", "X", "Y", etc., on the enclosed Search Report according to MPEP 609.

INFORMATION DISCLOSURE STATEMENT

Page 2

Serial No :10/816,804

Dkt: 1339.016US1

Filing Date: April 02, 2004

Title: ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any U.S. Patents or the Published Application cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

ROBERT M. CARLSON ET AL.

By their Representatives,


SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3261

Date 8/11/05

By 
Gary J. Speier
Reg. No. 45,458

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 11th day of August, 2005.


JAMES KANYOSIK
Name


Signature

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 1 of 10

Complete if Known

Application Number	10/816,804
Filing Date	April 2, 2004
First Named Inventor	Carlson, Robert
Group Art Unit	1617
Examiner Name	Unknown

Attorney Docket No: 1339.016US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2003/0008021 A1	01/09/2003	Babish, J. G., et al.	06/20/2001
	US-3,198,702	08/03/1965	Hellbaum, A. A.	03/17/1960
	US-3,966,925	06/29/1976	Bell, A. M.	12/24/1974
	US-3,989,817	11/02/1976	Mayer, F. S.	04/14/1972
	US-4,027,015	05/31/1977	Weinstein, M. J., et al.	06/09/1975
	US-4,045,420	08/30/1977	Soffer, M. J., et al.	05/29/1973
	US-4,083,986	04/11/1978	Pommer, E.-H., et al.	06/17/1977
	US-4,123,431	10/31/1978	Soffer, M. J., et al.	05/06/1977
	US-4,133,893	01/09/1979	Spangler, A. S.	05/26/1977
	US-4,153,683	05/08/1979	Stephan, W.	03/11/1977
	US-4,164,563	08/14/1979	Chang, R. W.	03/24/1975
	US-4,185,120	01/22/1980	Smith, R. A.	10/02/1978
	US-4,293,333	10/06/1981	Drobot, W.	02/12/1980
	US-4,294,852	10/13/1981	Wildnauer, R. H., et al.	08/21/1975
	US-4,311,639	01/19/1982	Ganfield, D. J., et al.	07/25/1980
	US-4,341,761	07/27/1982	Ganfeld, D. J., et al.	07/25/1980
	US-4,385,052	05/24/1983	Zackheim, H. S., et al.	07/20/1981
	US-4,388,462	06/14/1983	Pappo, R., et al.	07/20/1981
	US-4,427,684	01/24/1984	Ores, R. O.	09/24/1982
	US-4,438,030	03/20/1984	Ganfield, D. J., et al.	03/30/1982
	US-4,444,748	04/24/1984	Noble, R. E.	11/16/1982
	US-4,474,798	10/02/1984	Inagi, T., et al.	04/25/1983
	US-4,512,978	04/23/1985	Inwood, L. R.	10/15/1982
	US-4,525,359	06/25/1985	Greenway, III, F. L., et al.	12/10/1982
	US-4,588,724	05/13/1986	Greenway, III, F. L., et al.	01/11/1985
	US-4,593,038	06/03/1986	Burzynski, S. R.	04/03/1985
	US-4,623,664	11/18/1986	Schoenwald, R. D., et al.	10/31/1985
	US-4,626,529	12/02/1986	Grollier, J. F.	11/20/1984
	US-4,678,668	07/07/1987	Darras, R. L.	10/28/1985
	US-4,725,438	02/16/1988	Leazer, B. S.	05/29/1986
	US-4,753,958	06/28/1988	Weinstein, G. D., et al.	06/25/1986
	US-4,775,678	10/04/1988	Su, C.-C., et al.	05/08/1986
	US-4,785,013	11/15/1988	Margossian, A.	06/06/1984
	US-4,828,825	05/09/1989	Weber, P., et al.	09/15/1986
	US-4,839,159	06/13/1989	Winter, S. C., et al.	02/08/1988
	US-4,842,931	06/27/1989	Zook, G. P.	07/19/1988
	US-4,859,694	08/22/1989	Pavlich, F. M.	02/10/1988
	US-4,865,844	09/12/1989	Blank, L. B., et al.	05/20/1988

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/816,804
	Filing Date	April 2, 2004
	First Named Inventor	Carlson, Robert
	Group Art Unit	1617
	Examiner Name	Unknown
Sheet 2 of 10	Attorney Docket No: 1339.016US1	

	US-4,867,970	09/19/1989	Newsham, E A., et al.	05/21/1987
	US-4,893,620	01/16/1990	Wadwha, R. K.	02/18/1988
	US-4,895,727	01/23/1990	Allen, L. M.	05/03/1985
	US-4,945,084	07/31/1990	Packman, E. W.	07/08/1987
	US-4,968,361	11/06/1990	Ames, S. L., et al.	03/23/1989
	US-4,996,193	02/26/1991	Hewitt, C. W., et al.	03/03/1989
	US-5,002,938	03/26/1991	Wang, J., et al.	03/15/1989
	US-5,035,956	07/30/1991	Sedun, F. S.	08/09/1989
	US-5,045,366	09/03/1991	Sedun, F. S., et al.	10/03/1990
	US-5,057,500	10/15/1991	Thornfeldt, C. R.	02/12/1990
	US-5,110,809	05/05/1992	Wang, J., et al.	10/23/1990
	US-5,115,096	05/19/1992	Shoyab, M., et al.	01/17/1989
	US-5,116,603	05/26/1992	Friedman, Y.	01/18/1990
	US-5,134,119	07/28/1992	Lezdey, J., et al.	01/18/1991
	US-5,171,577	12/15/1992	Griat, J., et al.	12/06/1990
	US-5,188,817	02/23/1993	Ozick, J.	08/31/1990
	US-5,190,917	03/02/1993	Lezdey, J., et al.	04/11/1991
	US-5,209,932	05/11/1993	Nichols, L. D.	04/24/1992
	US-5,217,951	06/08/1993	Lezdey, J., et al.	10/18/1991
	US-5,219,571	06/15/1993	Wise, R. D.	05/13/1992
	US-5,219,877	06/15/1993	Shah, H. S., et al.	09/25/1989
	US-5,231,087	07/27/1993	Thornfeldt, C. R.	01/22/1992
	US-5,234,914	08/10/1993	Gallina, D. J.	11/27/1991
	US-5,252,331	10/12/1993	Curtis, A. W., et al.	03/05/1992
	US-5,262,149	11/16/1993	Sredni, B., et al.	08/13/1992
	US-5,290,762	03/01/1994	Lezdey, J., et al.	02/17/1993
	US-5,338,535	08/16/1994	Berndt, D. R.	12/23/1992
	US-5,352,442	10/04/1994	Proctor, P. H.	02/24/1993
	US-5,360,607	11/01/1994	Eyal, J., et al.	03/10/1992
	US-5,366,739	11/22/1994	MacKeen, D. L.	12/19/1992
	US-5,376,633	12/27/1994	Lezdey, J., et al.	09/15/1993
	US-5,389,092	02/14/1995	Guillemet, A., et al.	06/24/1992
	US-5,411,742	05/02/1995	Sebag, H., et al.	08/23/1993
	US-5,422,361	06/06/1995	Munayyer, F. J., et al.	06/27/1991
	US-5,428,012	06/27/1995	Shoyab, M., et al.	07/01/1993
	US-5,451,506	09/19/1995	Shoyab, M., et al.	06/16/1993
	US-5,470,869	11/28/1995	Taylor, P. N., et al.	01/31/1994
	US-5,470,876	11/28/1995	Proctor, P. H.	04/18/1994
	US-5,472,687	12/05/1995	Proctor, P. H.	02/07/1994
	US-5,474,760	12/12/1995	Ghio, A. J., et al.	03/29/1994
	US-5,496,811	03/05/1996	Aviv, H., et al.	01/05/1993
	US-5,512,270	04/30/1996	Ghio, A. J., et al.	08/31/1994
	US-5,532,215	07/02/1996	Lezdey, J., et al.	10/03/1994

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/816,804</td> </tr> <tr> <td>Filing Date</td> <td>April 2, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Carlson, Robert</td> </tr> <tr> <td>Group Art Unit</td> <td>1617</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> </table>	Application Number	10/816,804	Filing Date	April 2, 2004	First Named Inventor	Carlson, Robert	Group Art Unit	1617	Examiner Name	Unknown
Application Number	10/816,804										
Filing Date	April 2, 2004										
First Named Inventor	Carlson, Robert										
Group Art Unit	1617										
Examiner Name	Unknown										
Sheet 3 of 10	Attorney Docket No: 1339.016US1										

	US-5,534,246	07/09/1996	Herb, C. A., et al.	08/29/1994
	US-5,536,743	07/16/1996	Borgman, R. J.	08/24/1994
	US-5,556,875	09/17/1996	Truong, T. V., et al.	08/24/1995
	US-5,597,849	01/28/1997	McGinity, J. W., et al.	11/14/1994
	US-5,618,715	04/08/1997	Shoyab, M., et al.	06/10/1993
	US-5,621,008	04/15/1997	Ptchelintsev, D.	10/27/1995
	US-5,622,993	04/22/1997	McGinity, J. W., et al.	09/01/1995
	US-5,626,856	05/06/1997	Berndt, D.	06/30/1995
	US-5,633,147	05/27/1997	Meissner, P. S., et al.	03/08/1994
	US-5,643,899	07/01/1997	Elias, P. M., et al.	02/27/1995
	US-5,658,586	08/19/1997	Rajaiah, J., et al.	10/28/1994
	US-5,668,168	09/16/1997	Truong, T. V., et al.	06/06/1995
	US-5,679,351	10/21/1997	Walter, J. F., et al.	06/07/1995
	US-5,681,851	10/28/1997	Lee, J., et al.	06/07/1995
	US-5,688,981	11/18/1997	Nanomura, A. M.	11/21/1996
	US-5,693,625	12/02/1997	Barritault, D., et al.	03/24/1994
	US-5,696,105	12/09/1997	Hackler, W. A.	03/14/1996
	US-5,698,533	12/16/1997	Kang, M.-C.	07/26/1994
	US-5,714,482	02/03/1998	Proctor, P. H.	06/05/1995
	US-5,714,510	02/03/1998	Proctor, P. H.	06/05/1995
	US-5,716,947	02/10/1998	Proctor, P. H.	06/05/1995
	US-5,723,502	03/03/1998	Proctor, P. H.	06/05/1995
	US-5,728,714	03/17/1998	Proctor, P. H.	06/05/1995
	US-5,733,572	03/31/1998	Unger, Evan C., et al.	11/29/1994
	US-5,733,870	03/31/1998	Alm, P.	10/04/1993
	US-5,744,442	04/28/1998	Richards, C. D., et al.	08/26/1992
	US-5,750,142	05/12/1998	Friedman, D., et al.	04/11/1997
	US-5,762,945	06/09/1998	Ashley, P., et al.	04/05/1996
	US-5,767,135	06/16/1998	Fernandez-Pol, J. A.	12/29/1995
	US-5,789,387	08/04/1998	Hector, R. F., et al.	08/27/1996
	US-5,811,111	09/22/1998	McAtee, D. M., et al.	04/03/1997
	US-5,814,341	09/29/1998	Fankhauser, P., et al.	08/12/1996
	US-5,827,531	10/27/1998	Morrison, D. R., et al.	12/02/1994
	US-5,830,436	11/03/1998	Ghio, A. J., et al.	03/30/1995
	US-5,840,277	11/24/1998	Ghio, A. J., et al.	04/15/1996
	US-5,840,310	11/24/1998	Wambebe, C. O.	08/06/1997
	US-5,840,744	11/24/1998	Borgman, R. J.	07/15/1996
	US-5,853,755	12/29/1998	Foldvari, M.	06/10/1997
	US-5,863,544	01/26/1999	Willcox, N., et al.	12/14/1995
	US-5,874,479	02/23/1999	Martin, A.	02/05/1998
	US-5,874,536	02/23/1999	Linsley, P. S., et al.	12/03/1991
	US-5,880,172	03/09/1999	Rajaiah, J., et al.	10/25/1996
	US-5,904,854	05/18/1999	Shmidt, J. L., et al.	01/31/1997

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/816,804
Filing Date	April 2, 2004
First Named Inventor	Carlson, Robert
Group Art Unit	1617
Examiner Name	Unknown

Sheet 4 of 10

Attorney Docket No: 1339.016US1

	US-5,916,769	06/29/1999	Olsen, H. S., et al.	04/11/1997
	US-5,933,864	08/10/1999	Boykins, T. L.	06/22/1998
	US-5,972,361	10/26/1999	Fowler, T. J., et al.	10/25/1996
	US-5,977,176	11/02/1999	Wise, R. D., et al.	11/19/1996
	US-5,980,898	11/09/1999	Glenn, G. M., et al.	07/17/1997
	US-5,980,931	11/09/1999	Fowler, T. J., et al.	11/19/1997
	US-5,994,330	11/30/1999	El Khoury, G. F.	11/09/1998
	US-5,994,399	11/30/1999	McKee, R. N., et al.	03/27/1997
	US-6,004,780	12/21/1999	Soppet, D. R., et al.	03/26/1997
	US-6,011,022	01/04/2000	El Khoury, G. F.	05/21/1998
	US-6,013,259	01/11/2000	de la Pena, N. E., et al.	09/22/1997
	US-6,024,940	02/15/2000	Ghio, A. J., et al.	06/16/1998
	US-6,063,397	05/16/2000	Fowler, T. J., et al.	10/25/1996
	US-6,074,655	06/13/2000	Fowler, T. J., et al.	02/08/1999
	US-6,074,839	06/13/2000	Meissner, P. S., et al.	06/06/1995
	US-6,075,056	06/13/2000	Quigley, Jr., J. W., et al.	10/03/1997
	US-6,086,789	07/11/2000	Brunengraber, H., et al.	05/12/1998
	US-6,086,881	07/11/2000	Frey, A., et al.	05/15/1998
	US-6,093,414	07/25/2000	Capelli, C. C.	08/11/1997
	US-6,099,892	08/08/2000	Masden, P. R., et al.	10/01/1998
	US-6,103,267	08/15/2000	Mitchnick, M. A., et al.	07/27/1998
	US-6,103,498	08/15/2000	Lawrence, D. A., et al.	04/11/1997
	US-6,113,921	09/05/2000	Friedman, D., et al.	01/13/1998
	US-6,117,904	09/12/2000	Murphy, D. M., et al.	09/03/1999
	US-6,127,393	10/03/2000	Fernandez-Pol, J. A.	08/01/1998
	US-6,132,746	10/17/2000	Hasenoehtl, E. J., et al.	05/22/1997
	US-6,133,440	10/17/2000	Qiu, Z., et al.	10/09/1998
	US-6,143,278	11/07/2000	Elkhoury, G. F.	02/23/1998
	US-6,150,405	11/21/2000	Proctor, P. H.	06/07/1995
	US-6,153,208	11/28/2000	McAtee, D. M., et al.	09/11/1998
	US-6,160,200	12/12/2000	Ehrnsperger, B. J., et al.	06/29/1998
	US-6,190,678	02/20/2001	Hasenoehtl, E. J., et al.	09/04/1998
	US-6,203,803	03/20/2001	De La Charriere, O., et al.	06/24/1997
	US-6,210,680	04/03/2001	Jin, Q., et al.	06/11/1999
	US-6,262,020	07/17/2001	Lezdey, J., et al.	02/15/2000
	US-6,262,041	07/17/2001	Serbinova, E.	04/06/1999
	US-6,262,063	07/17/2001	El Khoury, G. F.	11/06/2000
	US-6,265,543	07/24/2001	Meissner, P. S., et al.	08/20/1997
	US-6,271,214	08/07/2001	Qiu, Z., et al.	04/21/1999
	US-6,281,239	08/28/2001	Glassman, D.	04/12/2000
	US-6,284,739	09/04/2001	Grogli, M., et al.	03/03/1994
	US-6,299,771	10/09/2001	Shmidt, J. L., et al.	05/12/1999
	US-6,312,698	11/06/2001	Shahi, S. K., et al.	03/29/2000

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/816,804
Filing Date	April 2, 2004
First Named Inventor	Carlson, Robert
Group Art Unit	1617
Examiner Name	Unknown

Sheet 5 of 10

Attorney Docket No: 1339.016US1

	US-6,312,703	11/06/2001	Orthoefer, F. T.	02/05/1999
	US-6,333,042	12/25/2001	De La Charriere, O. , et al.	06/01/2000
	US-6,340,467	01/22/2002	Morrison, D. S.	02/19/1997
	US-6,359,190	03/19/2002	Ter-Ovanesyan, E. , et al.	08/21/2000
	US-6,365,410	04/02/2002	Schellenberger, V. , et al.	05/19/1999
	US-6,372,951	04/16/2002	Ter-Ovanesyan, E. , et al.	06/22/2000
	US-6,387,260	05/14/2002	Pimenov, A. V., et al.	02/17/2000
	US-6,391,185	05/21/2002	Shvarev, A. E., et al.	09/22/2000
	US-6,656,970	12/02/2003	Burman, A. C., et al.	03/08/2001
	US-H672	09/05/1989	Baxter, T. H., et al.	12/31/1986

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	EP-0093563A2	11/09/1983	Inagi, T., et al.	
	EP-0824913A2	02/25/1998	Gers-Barlag, Dr., H., et al.	
	EP-1031348A2	08/30/2000	Nonomura, M., et al.	
	FR-2097048 (w/ English Abstract)	03/03/1992	Belfield, W. O.	
	GB-0014768	11/09/1911	Kohler, J. R.	
	GB-2051575	01/21/1981	Bernard, P., et al.	
	JP-01-290619 (w/ English Abstract)	11/02/1989	Suzuki, H., et al.	
	JP-11-012122 (w/ English Abstract)	01/19/1999	Kitada, Y., et al.	
	WO-90/10441A1	09/20/1990	Thornfeldt, C. R.	
	WO-98/06260A1	02/19/1998	Capeli, C. C.	
	WO-01/17526A1	03/15/2001	Murphy, D. M.	
	WO-02/26761A1	04/04/2002	Krasutsky, P. A., et al.	
	WO-03/092712A1	11/13/2003	Fotinos, S., et al.	
	WO-2004/089357A2	10/21/2004	Carlson, R. M., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"Children's Medical Ventures - Aquaphor®", (Information relating to Aquaphor®), http://www.childmed.com/products/showprod.asp?fldAuto-19 , (Observed August 6, 2002), 1 pg.	
		"DERMAdoctor.com - your on-line source for skincare", (Information relating to Aquaphor® Healing Ointment), (Observed August 6, 2002), 2 pgs.	
		"drugstore.com - Aquaphor® store", (Information relating to Aquaphor® Healing Ointment), (Observed August 6, 2002), 3 pgs.	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/816,804
Filing Date	April 2, 2004
First Named Inventor	Carlson, Robert
Group Art Unit	1617
Examiner Name	Unknown

Sheet 6 of 10

Attorney Docket No: 1339.016US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"Eucerin. The Source for Serious Skin Care. Aquaphor® Helps Heal Skin.", http://www.eucerinus.com/skincare/moisturizingandhealing/handandbody/aquaphor/frame1.html , (Observed August 6, 2002), 2 pgs.	
		"Gradedons' Guide to Unique Uses for Vicks", <u>The People's Pharmacy</u> , http://www.healthcentral.com/peoplespharmacy/pp_guides/PDF/vicks02.pdf , (2002), 4 pgs.	
		International Search Report for corresponding PCT Application No. PCT/US2004/010351 (Attorney Docket No. 1339.016WO1) (October 21, 2004), 6 pgs.	
		"Pediatrix Medical Group - Parent's Guide - Medications in the NICU", (Information relating to Aquaphor®), http://www.pediatix.com/parents/Neonatal_Medicine/Medications/medication-skinaquaphor.html , (Observed August 6, 2002), 1 pg.	
		"Penlac™ Nail Lacquer Product Information", Manufactured by Aventis Pharma Deutschland GmbH, (2000), 2 pgs.	
		"Toenail and Foot Conditions Archives", http://askwaltstollmd.com/archives/toe/106551.html , (Observed September 30, 2002), 3 pgs.	
		"Treating Nail Fungus With Penlac™", http://www.dermilk.com/prod/penlac/penlac.html , (Observed March 17, 2001), 1 pg.	
		ALI-SHTAYEH, M. S., et al., "Antifungal Activity of Plant Extracts Against Dermatophytes", <u>Mycoses</u> , 42, (1999), 665-672	
		ALLEN, L. V., "Compounding Topical Dosage Forms: Ointments, Creams, Pastes and Lotions", <u>Secundum Artem - Current and Practical Compounding Information for the Pharmacist</u> , 3(2), (Paddock Laboratories, Inc.), http://www.paddocklabs.com/publications/secundum/secart32.html , (1993), 11 pgs.	
		ASHBURY, H. H., "An Ointment for the Relief of Discomfort Due to Severe Irradiation Epidermitis", <u>Radiology</u> , 36, (1941), 739	
		BAER, R. L., et al., "Attempts at Passive Transfer of Allergic Eczematous Sensitivity in Man", <u>The Journal of Investigative Dermatology</u> , 18, (1952), 53-59	
		BAKER, S. F., et al., "Skin Care Management Practices for Premature Infants", <u>Journal of Perinatology</u> , 19(6), (1999), 426-431	
		BANAKAR, U. V., "In vitro Release of Metoprolol from Various Transdermal Formulations", <u>Die Pharmazie</u> , 45(2), (1990), 121-123	
		BARON, B., et al., "Preparations of Phenylmercuric Benzoate and Their Bactericidal Value", <u>Journal of the American Pharmaceutical Association</u> , 32, (1943), 294-298	
		BAUMANN, L. S., et al., "The Effects of Topical Vitamin E on the Cosmetic Appearance of Scars", <u>Dermatologic Surgery</u> , 25(8), (1999), 311-315	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/816,804
Filing Date	April 2, 2004
First Named Inventor	Carlson, Robert
Group Art Unit	1617
Examiner Name	Unknown

Sheet 7 of 10

Attorney Docket No: 1339.016US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BAUTISTA, M. I., et al., "Characterization of Vernix Caseosa as a Natural Biofilm: Comparison to Standard Oil-Based Ointments", <u>Pediatric Dermatology</u> , 17(4), (2000), 253-260	
		BEAL, H. M., et al., "Prescription Uses of Emulsion Vehicles", <u>Journal of the American Pharmaceutical Association, Practical Pharmacy Edition</u> , 13(9), (1952), 672-673	
		BELSITO, D. V., "The Role of Tar in Goeckerman Therapy", <u>Archives of Dermatology</u> , 118(50), (1982), 319-321	
		BILLUPS, N. F., "Drug Release From Ointment Bases: Characteristics, Measurement and Evaluation - III. - Microbiological "Agar Tube" Method", <u>Canadian Journal of Pharmaceutical Sciences</u> , 4(1), (1969), 11-13	
		BROWN, B. E., et al., "Fate of Topical Hydrocarbons in the Skin", <u>Journal of the Society of Cosmetic Chemists</u> , 46, (1995), 1-9	
		BÜHLER, H., et al., "Inhibition of Rat Renal 11 β -Hydroxysteroid Dehydrogenase by Steroidal Compounds and Triterpenoids; Structure/Function Relationship", <u>Biochimica et Biophysica Acta (BBA) - General Subjects</u> , 1075(3), (1991), 206-211	
		CARTER, Y. M., et al., "Incidence of the Concrete Scalp Deformity Associated With Deep Scalp Donor Sites and Management With the Unna Cap", <u>Journal of Burn Care and Rehabilitation</u> , 20(2), (1999), 141-144	
		DAS GUPTA, V., et al., "Selection of a Best Base for the Hydrocortisone Ointment", <u>The Indian Journal of Hospital Pharmacy</u> , 10(4), (1973), 141-144	
		DIPRETA, E. A., et al., "Cholesterol Metabolism Defect Associated With Conradi-Hunerman-Happle Syndrome", <u>International Journal of Dermatology</u> , 39(11), (2000), 846-858	
		FAHLBERG, W. J., et al., "Development of Hypersensitivity to Thiamine Hydrochloride", <u>The Journal of Allergy</u> , 28, (1957), 414-417	
		FRERICH, W., et al., "Behandlung Leichter und Schwere EPH-Gestosen mit Xipamid (Aquaphor) : Therapy of Easy and Severe EPH Gestoses Using Xipamid (Aquaphor)", <u>Die Medizinische Welt</u> , 24(33), (1973), 1273-1274	
		FREUND, J., et al., "Sensitization to Horse Serum by Means of Adjuvants", <u>Proceedings of the Society for Experimental Biology and Medicine</u> , 49, (1942), 548-553	
		GOLDMAN, M. P., et al., "Optimizing Wound Healing in the Face After Laser Abrasion", <u>J. Am. Acad. Dermatol.</u> , 46, (2002), 399-407	
		HEGGERS, J. P., et al., "Effect of the Combination of <i>Aloe vera</i> , Nitroglycerin, and L-NAME on Wound Healing in the Rat Excisional Model", <u>The Journal of Alternative and Complementary Medicine</u> , 3(2), (1997), 149-153	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/816,804
Filing Date	April 2, 2004
First Named Inventor	Carlson, Robert
Group Art Unit	1617
Examiner Name	Unknown

Sheet 8 of 10

Attorney Docket No: 1339.016US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HEMPELMANN, F. W., et al., "Die Hemmung der Carboanhydrase durch Xipamid (4-Chlor-5-Sulfamoyl-2', Salicyloxylylid) im Modifizierten Philpot-Test : Inhibition of Carbonic Anhydrase by Xipamide (4-Chloro-Sulfamoyl-2', 6'-Salicyloxylylids in the Modified Philpot Test" (English Abstract), <u>Arzneimittel-Forschung/ Drug Research</u> , 25(2), (1975), 259-260	
		HEMPELMANN, F. W., et al., "Die Saluretische Wirkung von Xipamid (4-Chlor-5-Sulfamoyl-2', 6'-Salicyloxylylid) bei Gesunden Probanden : The Saluretic Effect of Xipamide (4-Chlor-5-Sulfamoyl-2', 6'-Salicyloxylylids) in Normal Subjects" (English Abstract), <u>Arzneimittel-Forschung/ Drug Research</u> , 25(2), (1975), 252-255	
		HEMPELMANN, V. F., et al., "Untersuchungen mit Xipamid (4-Chlor-5-sulfamoyl-2', 6'-salicyloxylylid) : Studies on Xipamide (4-chloro-5-sulfamoyl-2', 6'-salicyloxylylids). Part 1: Physico-chemical and chemical properties" (English Abstract), <u>Arzneimittel Forschung/ Drug Research</u> , 27(11), (1977), 2140-2142	
		HENSEN, J. P., "Local Antihistaminic Action", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 100, (1950), 136-140	
		HOKAMA, Y., et al., "Effect of Drugs on Cx-Protein Responses in the Rabbit", <u>Proceedings of the Society for Experimental Biology and Medicine</u> , 105, (1960), 510-514	
		HOWZE, J. M., et al., "Drug Release from Ointment Bases: Characteristics, Measurement and Evaluation-II. Dialysis Cell Method", <u>American Journal of Pharmacy</u> , 138(5), (1966), 193-203	
		HUSA, W. J., et al., "The Antiseptic Value of Phenol Ointments", <u>Journal of the American Pharmaceutical Association</u> , 21, (1932), 861-869	
		KIES, M. W., "Occurrence of Lipemia in Experimental Allergic Encephalomyelitis", <u>Neurology</u> , VII, (1957), 175-188	
		KOCH, H. P., "In Vitro Inhibition of Adenosine Deaminase by a Group of Steroid and Triterpenoid Compounds", <u>Phytotherapy Research</u> , 8, (1994), 109-111	
		KOLB, L. C., et al., "Prevention of Experimental Allergic Encephalomyelitis by Various Agents", <u>Transactions of the American Neurological Association</u> , 77, (1952), 117-121	
		KOPELOFF, L. M., et al., "Recurrent Convulsive Seizures in Animals Produced by Immunologic and Chemical Means", <u>The American Journal of Psychiatry</u> , 98(4), (1942), 881-902	
		LEE, J. M., et al., "Critical Relationships Between Constituents of the Antigen-Adjuvant Emulsion Affecting Experimental Allergic Encephalomyelitis in a Completely Susceptible Mouse Genotype", <u>The Journal of Experimental Medicine</u> , 115, (1962), 157-167	
		LEIFER, W., et al., "Studies in Sensitization to Halogenated Hydroxyquinolines and Related Compounds", <u>The Journal of Investigative Dermatology</u> , 17, (1951), 233-240	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="padding: 2px;">Complete if Known</td> </tr> <tr> <td style="width: 40%; padding: 2px;">Application Number</td> <td style="padding: 2px;">10/816,804</td> </tr> <tr> <td style="padding: 2px;">Filing Date</td> <td style="padding: 2px;">April 2, 2004</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">Carlson, Robert</td> </tr> <tr> <td style="padding: 2px;">Group Art Unit</td> <td style="padding: 2px;">1617</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">Unknown</td> </tr> </table>	Complete if Known		Application Number	10/816,804	Filing Date	April 2, 2004	First Named Inventor	Carlson, Robert	Group Art Unit	1617	Examiner Name	Unknown
Complete if Known													
Application Number	10/816,804												
Filing Date	April 2, 2004												
First Named Inventor	Carlson, Robert												
Group Art Unit	1617												
Examiner Name	Unknown												
Sheet 9 of 10	Attorney Docket No: 1339.016US1												

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LEUSCHNER, F., et al., "Pharmakologische und Toxikologische Eigenschaften des Saluretikums Xipamid (4-Chlor-5-Sulfamoyl-2', 6'-Salicyloxylylid) : Pharmacological and Toxicological Properties of the Saluretic Xipamide (4-Chloro-5-Sulfamoyl-2', 6'-Salicyloxylylide)" (English Abstract), <u>Arzneimittel-Forschung/ Drug Research</u> , 25(2), (1975),245-51	
		LIEBENOW, W., et al., "Struktur-Wirkungsbeziehungen beim Diuretikum Xipamid (4-Chlor-5-Sulfamoyl-2'-Salicyloxylylid) : Structure-Activity Relationships in the Diuretic Xipamide (4-Chlor-5-Sulfamoyl-2', 6' -Salicyloxylylide)" (English Abstract), <u>Arzneimittel-Forschung/ Drug Research</u> , 25(2), (1975),240-246	
		LIN, R. Y., et al., "Topical Zinc Sulfate Augmentation of Human Delayed Type Skin Test Response", <u>Acta Derm Venereol</u> , 65, (1985), 190-193	
		LITTLE, J. W., et al., "Effect of Aquaphor Ointment on Wound Healing", <u>Journal of Dental Research</u> , 51(6), (1972), 1672-1674	
		LOZADA, H. A., et al., "Hydrogen Peroxide Formation by Zinc Oxide in Ointments", <u>Drug Standards</u> , 28(3), (1960), 73-76	
		MAGUIRE, D. P., "Skin Protection and Breakdown in the ELBW Infant", <u>Clinical Nursing Research</u> , 8(3), (1999),222-234	
		MAWAD, J. , "Erfahrungen mit Xipamid (Aquaphor) in der Geriatrie : (Experiences With Xipamid (Aquaphor) in Geriatrics)", <u>Die Medizinische Welt</u> , 25(21), (1974), 954-955	
		MILBERG, I. L., et al., "The Effects of Certain Vehicles and of Salt Solutions Upon Reactive Hyperemia in the Skin: Application in a Case of Lichen Ruber Plants", <u>The Journal of Investigative Dermatology</u> , 5, (1942), 403-410	
		NELDNER, K. H., "Prevention of Skin Cancer with Topical 5-Fluorouracil", <u>Rocky Mountain Medical Journal</u> , 63(11), (1966),74-78	
		NOURI, K , et al., "Topical Treatment of Psoriasis With Fludarabine", <u>Cutis</u> , 59(5), (1997), 284	
		PABST, R. C., et al., "The Effect of Application of Aquaphor on Skin Condition, Fluid Requirements, and Bacterial Colonization in Very Low Birth Weight Infants", <u>Journal of Perinatology</u> , 19(4), (1999), 278-283	
		PATEL, U. et al., "Comparative <i>in Vitro</i> Dermatokinetics of Ibuprofen (IBP)", <u>II Farmaco</u> , 45(5), (1990), 559-568	
		PICKENS, W. L., et al., "Characterization of Vernix Caseosa: Water Content, Morphology, and Elemental Anaysis", <u>The Journal of Investigative Dermatology</u> , 115(5), (2000), 875-881	
		PLAKOGIANNIS, F. M., et al., "Influence of Ointment Bases on the in vitro Release of Methyl Salicylate", <u>Pharmaceutica Acta Helvetiae</u> , 52(10), (1977),236-238	
		RODRIGUEZ, J. T., et al., "Treatment of Skin Irritation Around Enterostomies With Cholestyramine Ointment", <u>The Journal of Pediatrics</u> , 88(No. 4, Part 1), (1976), 659-661	

EXAMINER

DATE CONSIDERED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<i>Complete if Known</i>	
	Application Number	10/816,804
	Filing Date	April 2, 2004
	First Named Inventor	Carlson, Robert
	Group Art Unit	1617
	Examiner Name	Unknown
Sheet 10 of 10	Attorney Docket No: 1339.016US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SIDWELL, R. W., et al., "Influence of Vehicle on Topical Efficacy of 2-Acetylpyridine Thiosemicarbazone and Related Derivatives on in vivo Type 2 Herpes Simplex Virus Infections", <u>Chemotherapy</u> , 36, (1990), 58-69	
		SKAUEN, D. M., et al., "A Study of the Absorption of Radioactive Sodium Iodide from a Variety of Ointment Bases", <u>Journal of the American Pharmaceutical Association - Scientific Edition</u> , 38(1), (1949), 618-619	
		SORENSEN, K. N., et al., "Efficacy of Syringomycin E in a Murine Model of Vaginal Candidiasis", <u>The Journal of Antibiotics</u> , 51(8), (1998), 743-749	
		STRAKOSCH, M.D., E. A., "The Role of Bases in Ointments Used for Protection Against Sunlight", <u>The Journal of Investigative Dermatology</u> , 5, (1942), 1-5	
		SUMMER, G. J., "The Unna "Cap" As a Scalp Donor Site Dressing", <u>Journal of Burn Care and Rehabilitation</u> , 20(2), (1999), 183-188	
		TANZI, E. L., et al., "The Effect of a Mucopolysaccharide-Cartilage Complex Healing Ointment on Er:YAG Laser Resurfaced Facial Skin", <u>Dermatologic Surgery</u> , 28(4), (2002), 305-308	
		WAKSMAN, B. H., et al., "A Comparative Study of Experimental Allergic Neuritis in the Rabbit, Guinea Pig, and Mouse", <u>Journal of Neuropathology and Experimental Neurology</u> , Vol. XV, (1956), 293-331	
		WEDIG, J. H., et al., "Teratologic Evaluation of Dermal Applied Zinc Pyrithione on Swine", <u>Toxicology and Applied Pharmacology</u> , 36, (1976), 255-259	
		WOOD, H. F., "The Relationship Between the Acute Phase Response and Antibody Production in the Rabbit. II. The Stimulation of Cx-Reactive Protein Response by Certain Adjuvants and the Relation of this Response to the Enhancement of Antibody Formation", <u>Journal of Experimental Medicine</u> , 98, (1953), 321-329	
		YOUMANS, G. P., et al., "Preparation and Effect of Different Adjuvants on the Immunogenic Activity of Mycobacterial Ribosomal Functions", <u>Journal of Bacteriology</u> , 94(4), (1967), 836-843	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached